Delirium, Agitation/Sedation, Pain and Dyspnea in Respiratory Intensive Care Unit (NIVILIUM)

Sponsor
University of Modena and Reggio Emilia (Other)
Overall Status
Recruiting
CT.gov ID
NCT03880084
Collaborator
(none)
92
1
65.1
1.4

Study Details

Study Description

Brief Summary

Non-Invasive Mechanical Ventilation (NIV) has been increasingly used in the treatment of acute respiratory failure. Notwithstanding failure rates still remains high, ranging from 5% to 60%. The onset of delirium, agitation, pain and dyspnea may contribute to reduce the success rate of non invasive ventilation treatment. The aim of this study is to assess the incidence and impact of delirium, agitation, pain and dyspnea on clinical outcomes in a population of patient admitted to Respiratory Intensive Care Unit undergoing Non-Invasive Mechanical Ventilation for Acute Respiratory Failure.

Condition or Disease Intervention/Treatment Phase
  • Other: Observation

Study Design

Study Type:
Observational
Anticipated Enrollment :
92 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Longitudinal Assessment of Delirium, Agitation/Sedation, Pain and Dyspnea in Patients Admitted to Respiratory Intensive Care Unit for Acute Respiratory Failure (NIVILIUM)
Actual Study Start Date :
Aug 1, 2019
Actual Primary Completion Date :
Aug 1, 2020
Anticipated Study Completion Date :
Jan 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Incidence of delirium [7 days from Respiratory Intensive Care Unit admission]

    The onset of delirium will be assessed through the Confusion Assessment Method for Intensive Care Unit 7 scale, ranges 0-7, values > 2 indicate the presence of delirium

  2. Incidence of agitation [7 days from Respiratory Intensive Care Unit admission]

    The onset of delirium will be assessed through the Richmond Agitation Sedation Scale ranges +4 to -5, values > 0 indicate the presence of agitation, values < 0 indicate the presence of sedation

  3. Incidence of pain [7 days from Respiratory Intensive Care Unit admission]

    The onset of delirium will be assessed through the Behavioral Pain Scale, ranges 3-12, values > 4 indicate the presence of pain

  4. Incidence of dyspnea [7 days from Respiratory Intensive Care Unit admission]

    The onset of delirium will be assessed through the Borg scale, ranges 0-10, values > 0 indicate the presence of dyspnea

Secondary Outcome Measures

  1. The impact of delirium on Non Invasive Ventilation Success [30 days from Respiratory Intensive Care Unit admission]

    The correlation between the onset of delirium and the failure rates of Non Invasive Ventilation Treatment will be assessed

  2. The impact of agitation on Non Invasive Ventilation Success [30 days from Respiratory Intensive Care Unit admission]

    The correlation between the onset of agitation and the failure rates of Non Invasive Ventilation Treatment will be assessed

  3. The impact of pain on Non Invasive Ventilation Success [30 days from Respiratory Intensive Care Unit admission]

    The correlation between the onset and level of pain and the failure rates of Non Invasive Ventilation Treatment will be assessed

  4. The impact of dyspnea on Non Invasive Ventilation Success [30 days from Respiratory Intensive Care Unit admission]

    The correlation between the onset and level of dyspnea and the failure rates of Non Invasive Ventilation Treatment will be assessed

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • patients with acute respiratory failure admitted to the Respiratory Intensive Care Unit of the University Hospital of Modena undergoing non invasive mechanical ventilation
Exclusion Criteria:
  • age lower than 18

  • Glasgow Coma Scale lower than 10 within 24 hours from Respiratory Intensive Care Unit admission

  • need for immediate orotracheal intubation

  • pregnancy

  • previously established psychiatric disease or dementia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Azienda Ospedaliero Universitaria Policlinico di Modena Modena Italy

Sponsors and Collaborators

  • University of Modena and Reggio Emilia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alessandro Marchioni, Principal Investigator, University of Modena and Reggio Emilia
ClinicalTrials.gov Identifier:
NCT03880084
Other Study ID Numbers:
  • UModenaReggio 5
First Posted:
Mar 19, 2019
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2022